Wilkinson: What is the Deal with Esketamine?
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, writes in Psychiatric Times about the drug esketamine, approved by the U.S. Food and Drug Administration last year as the first rapid-acting therapy for treatment-resistant depression.
Wilkinson Honored with New Investigator Award from ISCTM
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, has been awarded a New Investigator Award from the International Society of CNS Clinical Trials and Methodology (ISCTM).
New depression drug related to ketamine recommended by FDA panel
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry; Director of the Yale Depression Research Program; and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service is featured in a NBC Nightly News report about the drug esketamine.
Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital
Yale researchers, including first author Samuel Wilkinson, MD, Assistant Professor of Psychiatry, describe in a paper published in Biological Psychiatry their experience providing ketamine as a clinical treatment to participants with severe and treatment-resistant mood disorders.
Depression treatments inspired by ketamine move ahead in tests
Antidepressant drugs that work in hours instead of weeks could be on the market within three years, researchers say. "I think it's highly probable that we'll see some version of one of these treatments being approved in the relatively near future," says Dr. Gerard Sanacora, director of the Yale Depression Research Program.
Suicide prevention and ketamine
Suicide, a significant public health problem, is closely linked with mental health conditions, especially depression. At the Yale Depression Research Clinic, a clinical trial is now underway to determine whether esketamine, a form of the drug ketamine, can help prevent suicide in depressed patients.
CME Opportunity: 4th Annual Psychopharmacology Master Class
The 4th Annual Psychopharmacology Master Class will be held on Friday, March 28, 2014. Certified for 6.5 AMA PRA Category 1 Credits (TM), the course will provide updates on recent clinical data and expert recommendations for the treatment of mood disorders with a specific focus on depression. Gerard Sanacora, MD, PhD, professor of psychiatry and director of the Yale Depression Research Program, is the course director.
New drug shows same antidepressant effect as ketamine, study shows
A drug under development seems to have similar antidepressant effects as previously observed with ketamine, but without the same level of dangerous side effects seen when the anesthetic is abused as a party drug, according to a new Yale-led study. Gerard Sanacora, MD, PhD, professor of psychiatry and director of the Yale Depression Research Program, is first author.
Ketamine & Depression: Changing Your State Of Mind -- In Depth Doctor's Interview
Ivanhoe Broadcast News interviews Dr. Gerard Sanacora about his research on ketamine and depression. He states, "A lot of our work is actually trying to understand the changes that occur, after a dosing of ketamine, that are associated with the clinical benefit."